Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men
Background The safety of active surveillance (AS) for African American men compared with non‐Hispanic White (White) men with intermediate‐risk prostate cancer is unclear. Methods The authors identified patients with modified National Comprehensive Cancer Network favorable (“low‐intermediate”) and un...
Gespeichert in:
| Veröffentlicht in: | Cancer 2021-12, Vol.127 (23), p.4403-4412 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4412 |
|---|---|
| container_issue | 23 |
| container_start_page | 4403 |
| container_title | Cancer |
| container_volume | 127 |
| creator | Courtney, P. Travis Deka, Rishi Kotha, Nikhil V. Cherry, Daniel R. Salans, Mia A. Nelson, Tyler J. Kumar, Abhishek Luterstein, Elaine Yip, Anthony T. Nalawade, Vinit Parsons, J. Kellogg Kader, A. Karim Stewart, Tyler F. Rose, Brent S. |
| description | Background
The safety of active surveillance (AS) for African American men compared with non‐Hispanic White (White) men with intermediate‐risk prostate cancer is unclear.
Methods
The authors identified patients with modified National Comprehensive Cancer Network favorable (“low‐intermediate”) and unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health Administration database. They analyzed definitive treatment, disease progression, metastases, prostate cancer–specific mortality (PCSM), and all‐cause mortality by using cumulative incidences and multivariable competing‐risks (disease progression, metastasis, and PCSM) or Cox (all‐cause mortality) regression.
Results
The cohort included 1007 men (African Americans, 330 [32.8%]; Whites, 677 [67.2%]) followed for a median of 7.7 years; 773 (76.8%) had low‐intermediate‐risk disease, and 234 (23.2%) had high‐intermediate‐risk disease. The 10‐year cumulative incidences of definitive treatment were not significantly different (African Americans, 83.5%; 95% confidence interval [CI], 78.5%‐88.7%; Whites, 80.6%; 95% CI, 76.6%‐84.4%; P = .17). Among those with low‐intermediate‐risk disease, there were no significant differences in the 10‐year cumulative incidences of disease progression (African Americans, 46.8%; 95% CI, 40.0%‐53.3%; Whites, 46.9%; 95% CI, 42.1%‐51.5%; P = .91), metastasis (African Americans, 7.1%; 95% CI, 3.7%‐11.8%; Whites, 10.8%; 95% CI, 7.6%‐14.6%; P = .17), or PCSM (African Americans, 3.8%; 95% CI, 1.6%‐7.5%; Whites, 3.8%; 95% CI, 2.0%‐6.3%; P = .69). In a multivariable regression including the entire cohort, African American race was not associated with increased risks of definitive treatment, disease progression, metastasis, PCSM, or all‐cause mortality (all P > .30).
Conclusions
Outcomes in the Veterans Affairs Health System were similar for African American and White men treated for low‐intermediate‐risk prostate cancer with AS.
The safety of active surveillance for African American men with intermediate‐risk prostate cancer is unclear. This study has measured similar clinical outcomes for African American men and non‐Hispanic White men treated for either modified National Comprehensive Cancer Network (NCCN) favorable (“low‐intermediate”) or unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer with active surveillance, and it suggests that active surveillance may be an appropriate op |
| doi_str_mv | 10.1002/cncr.33824 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2595120603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2595120603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3934-4a631a177ff035571656d7a88539b97ad112e11fc5b3848929c47060f7d6b7353</originalsourceid><addsrcrecordid>eNp9kN1KwzAYhoMobk5PvAAJeCZ05rdpD0tRJwwFUfQsZGmKmV02k3ayMy_Ba_RKzKx66FHywvO9-fIAcIzRGCNEzrXTfkxpRtgOGGKUiwRhRnbBECGUJZzRpwE4CGEeoyCc7oMBZZQJkuMhaArd2rWBofNrY5tGOW1gvfTQutb4hamsas3n-4e34QWu_DK0MUO9xbYMLGpvY4LFwvQX5Sroli6OTGxYKWc1fHy2cWZh3CHYq1UTzNHPOQIPlxf35SSZ3l5dl8U00TSnLGEqpVhhIeoaUc4FTnlaCZVlnOazXKgKY2IwrjWf0YxlOck1EyhFtajSmaCcjsBp3xsXfu1MaOV82XkXn5SE5xyTCNNInfWUjt8K3tRy5e1C-Y3ESG7Fyq1Y-S02wic_ld0sWvlDf01GAPfAm23M5p8qWd6Ud33pF-AvhII</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2595120603</pqid></control><display><type>article</type><title>Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Courtney, P. Travis ; Deka, Rishi ; Kotha, Nikhil V. ; Cherry, Daniel R. ; Salans, Mia A. ; Nelson, Tyler J. ; Kumar, Abhishek ; Luterstein, Elaine ; Yip, Anthony T. ; Nalawade, Vinit ; Parsons, J. Kellogg ; Kader, A. Karim ; Stewart, Tyler F. ; Rose, Brent S.</creator><creatorcontrib>Courtney, P. Travis ; Deka, Rishi ; Kotha, Nikhil V. ; Cherry, Daniel R. ; Salans, Mia A. ; Nelson, Tyler J. ; Kumar, Abhishek ; Luterstein, Elaine ; Yip, Anthony T. ; Nalawade, Vinit ; Parsons, J. Kellogg ; Kader, A. Karim ; Stewart, Tyler F. ; Rose, Brent S.</creatorcontrib><description>Background
The safety of active surveillance (AS) for African American men compared with non‐Hispanic White (White) men with intermediate‐risk prostate cancer is unclear.
Methods
The authors identified patients with modified National Comprehensive Cancer Network favorable (“low‐intermediate”) and unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health Administration database. They analyzed definitive treatment, disease progression, metastases, prostate cancer–specific mortality (PCSM), and all‐cause mortality by using cumulative incidences and multivariable competing‐risks (disease progression, metastasis, and PCSM) or Cox (all‐cause mortality) regression.
Results
The cohort included 1007 men (African Americans, 330 [32.8%]; Whites, 677 [67.2%]) followed for a median of 7.7 years; 773 (76.8%) had low‐intermediate‐risk disease, and 234 (23.2%) had high‐intermediate‐risk disease. The 10‐year cumulative incidences of definitive treatment were not significantly different (African Americans, 83.5%; 95% confidence interval [CI], 78.5%‐88.7%; Whites, 80.6%; 95% CI, 76.6%‐84.4%; P = .17). Among those with low‐intermediate‐risk disease, there were no significant differences in the 10‐year cumulative incidences of disease progression (African Americans, 46.8%; 95% CI, 40.0%‐53.3%; Whites, 46.9%; 95% CI, 42.1%‐51.5%; P = .91), metastasis (African Americans, 7.1%; 95% CI, 3.7%‐11.8%; Whites, 10.8%; 95% CI, 7.6%‐14.6%; P = .17), or PCSM (African Americans, 3.8%; 95% CI, 1.6%‐7.5%; Whites, 3.8%; 95% CI, 2.0%‐6.3%; P = .69). In a multivariable regression including the entire cohort, African American race was not associated with increased risks of definitive treatment, disease progression, metastasis, PCSM, or all‐cause mortality (all P > .30).
Conclusions
Outcomes in the Veterans Affairs Health System were similar for African American and White men treated for low‐intermediate‐risk prostate cancer with AS.
The safety of active surveillance for African American men with intermediate‐risk prostate cancer is unclear. This study has measured similar clinical outcomes for African American men and non‐Hispanic White men treated for either modified National Comprehensive Cancer Network (NCCN) favorable (“low‐intermediate”) or unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer with active surveillance, and it suggests that active surveillance may be an appropriate option for both African American men and non‐Hispanic White men with modified NCCN favorable (“low‐intermediate”) intermediate‐risk prostate cancer.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.33824</identifier><identifier>PMID: 34347291</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>active surveillance ; African American ; African Americans ; clinical outcomes ; Confidence intervals ; Health risks ; Humans ; intermediate‐risk prostate cancer ; Male ; Metastases ; Metastasis ; Minority & ethnic groups ; Mortality ; Oncology ; Prostate cancer ; Prostate-Specific Antigen ; Prostatic Neoplasms - pathology ; Risk ; Statistical analysis ; Surveillance ; Veterans Health Administration ; Watchful Waiting ; Whites</subject><ispartof>Cancer, 2021-12, Vol.127 (23), p.4403-4412</ispartof><rights>2021 American Cancer Society</rights><rights>2021 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3934-4a631a177ff035571656d7a88539b97ad112e11fc5b3848929c47060f7d6b7353</citedby><cites>FETCH-LOGICAL-c3934-4a631a177ff035571656d7a88539b97ad112e11fc5b3848929c47060f7d6b7353</cites><orcidid>0000-0002-3197-9552 ; 0000-0002-7783-0016 ; 0000-0001-7625-3678</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.33824$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.33824$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34347291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Courtney, P. Travis</creatorcontrib><creatorcontrib>Deka, Rishi</creatorcontrib><creatorcontrib>Kotha, Nikhil V.</creatorcontrib><creatorcontrib>Cherry, Daniel R.</creatorcontrib><creatorcontrib>Salans, Mia A.</creatorcontrib><creatorcontrib>Nelson, Tyler J.</creatorcontrib><creatorcontrib>Kumar, Abhishek</creatorcontrib><creatorcontrib>Luterstein, Elaine</creatorcontrib><creatorcontrib>Yip, Anthony T.</creatorcontrib><creatorcontrib>Nalawade, Vinit</creatorcontrib><creatorcontrib>Parsons, J. Kellogg</creatorcontrib><creatorcontrib>Kader, A. Karim</creatorcontrib><creatorcontrib>Stewart, Tyler F.</creatorcontrib><creatorcontrib>Rose, Brent S.</creatorcontrib><title>Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background
The safety of active surveillance (AS) for African American men compared with non‐Hispanic White (White) men with intermediate‐risk prostate cancer is unclear.
Methods
The authors identified patients with modified National Comprehensive Cancer Network favorable (“low‐intermediate”) and unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health Administration database. They analyzed definitive treatment, disease progression, metastases, prostate cancer–specific mortality (PCSM), and all‐cause mortality by using cumulative incidences and multivariable competing‐risks (disease progression, metastasis, and PCSM) or Cox (all‐cause mortality) regression.
Results
The cohort included 1007 men (African Americans, 330 [32.8%]; Whites, 677 [67.2%]) followed for a median of 7.7 years; 773 (76.8%) had low‐intermediate‐risk disease, and 234 (23.2%) had high‐intermediate‐risk disease. The 10‐year cumulative incidences of definitive treatment were not significantly different (African Americans, 83.5%; 95% confidence interval [CI], 78.5%‐88.7%; Whites, 80.6%; 95% CI, 76.6%‐84.4%; P = .17). Among those with low‐intermediate‐risk disease, there were no significant differences in the 10‐year cumulative incidences of disease progression (African Americans, 46.8%; 95% CI, 40.0%‐53.3%; Whites, 46.9%; 95% CI, 42.1%‐51.5%; P = .91), metastasis (African Americans, 7.1%; 95% CI, 3.7%‐11.8%; Whites, 10.8%; 95% CI, 7.6%‐14.6%; P = .17), or PCSM (African Americans, 3.8%; 95% CI, 1.6%‐7.5%; Whites, 3.8%; 95% CI, 2.0%‐6.3%; P = .69). In a multivariable regression including the entire cohort, African American race was not associated with increased risks of definitive treatment, disease progression, metastasis, PCSM, or all‐cause mortality (all P > .30).
Conclusions
Outcomes in the Veterans Affairs Health System were similar for African American and White men treated for low‐intermediate‐risk prostate cancer with AS.
The safety of active surveillance for African American men with intermediate‐risk prostate cancer is unclear. This study has measured similar clinical outcomes for African American men and non‐Hispanic White men treated for either modified National Comprehensive Cancer Network (NCCN) favorable (“low‐intermediate”) or unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer with active surveillance, and it suggests that active surveillance may be an appropriate option for both African American men and non‐Hispanic White men with modified NCCN favorable (“low‐intermediate”) intermediate‐risk prostate cancer.</description><subject>active surveillance</subject><subject>African American</subject><subject>African Americans</subject><subject>clinical outcomes</subject><subject>Confidence intervals</subject><subject>Health risks</subject><subject>Humans</subject><subject>intermediate‐risk prostate cancer</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Minority & ethnic groups</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Risk</subject><subject>Statistical analysis</subject><subject>Surveillance</subject><subject>Veterans Health Administration</subject><subject>Watchful Waiting</subject><subject>Whites</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN1KwzAYhoMobk5PvAAJeCZ05rdpD0tRJwwFUfQsZGmKmV02k3ayMy_Ba_RKzKx66FHywvO9-fIAcIzRGCNEzrXTfkxpRtgOGGKUiwRhRnbBECGUJZzRpwE4CGEeoyCc7oMBZZQJkuMhaArd2rWBofNrY5tGOW1gvfTQutb4hamsas3n-4e34QWu_DK0MUO9xbYMLGpvY4LFwvQX5Sroli6OTGxYKWc1fHy2cWZh3CHYq1UTzNHPOQIPlxf35SSZ3l5dl8U00TSnLGEqpVhhIeoaUc4FTnlaCZVlnOazXKgKY2IwrjWf0YxlOck1EyhFtajSmaCcjsBp3xsXfu1MaOV82XkXn5SE5xyTCNNInfWUjt8K3tRy5e1C-Y3ESG7Fyq1Y-S02wic_ld0sWvlDf01GAPfAm23M5p8qWd6Ud33pF-AvhII</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Courtney, P. Travis</creator><creator>Deka, Rishi</creator><creator>Kotha, Nikhil V.</creator><creator>Cherry, Daniel R.</creator><creator>Salans, Mia A.</creator><creator>Nelson, Tyler J.</creator><creator>Kumar, Abhishek</creator><creator>Luterstein, Elaine</creator><creator>Yip, Anthony T.</creator><creator>Nalawade, Vinit</creator><creator>Parsons, J. Kellogg</creator><creator>Kader, A. Karim</creator><creator>Stewart, Tyler F.</creator><creator>Rose, Brent S.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0002-3197-9552</orcidid><orcidid>https://orcid.org/0000-0002-7783-0016</orcidid><orcidid>https://orcid.org/0000-0001-7625-3678</orcidid></search><sort><creationdate>20211201</creationdate><title>Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men</title><author>Courtney, P. Travis ; Deka, Rishi ; Kotha, Nikhil V. ; Cherry, Daniel R. ; Salans, Mia A. ; Nelson, Tyler J. ; Kumar, Abhishek ; Luterstein, Elaine ; Yip, Anthony T. ; Nalawade, Vinit ; Parsons, J. Kellogg ; Kader, A. Karim ; Stewart, Tyler F. ; Rose, Brent S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3934-4a631a177ff035571656d7a88539b97ad112e11fc5b3848929c47060f7d6b7353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>active surveillance</topic><topic>African American</topic><topic>African Americans</topic><topic>clinical outcomes</topic><topic>Confidence intervals</topic><topic>Health risks</topic><topic>Humans</topic><topic>intermediate‐risk prostate cancer</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Minority & ethnic groups</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Risk</topic><topic>Statistical analysis</topic><topic>Surveillance</topic><topic>Veterans Health Administration</topic><topic>Watchful Waiting</topic><topic>Whites</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Courtney, P. Travis</creatorcontrib><creatorcontrib>Deka, Rishi</creatorcontrib><creatorcontrib>Kotha, Nikhil V.</creatorcontrib><creatorcontrib>Cherry, Daniel R.</creatorcontrib><creatorcontrib>Salans, Mia A.</creatorcontrib><creatorcontrib>Nelson, Tyler J.</creatorcontrib><creatorcontrib>Kumar, Abhishek</creatorcontrib><creatorcontrib>Luterstein, Elaine</creatorcontrib><creatorcontrib>Yip, Anthony T.</creatorcontrib><creatorcontrib>Nalawade, Vinit</creatorcontrib><creatorcontrib>Parsons, J. Kellogg</creatorcontrib><creatorcontrib>Kader, A. Karim</creatorcontrib><creatorcontrib>Stewart, Tyler F.</creatorcontrib><creatorcontrib>Rose, Brent S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Courtney, P. Travis</au><au>Deka, Rishi</au><au>Kotha, Nikhil V.</au><au>Cherry, Daniel R.</au><au>Salans, Mia A.</au><au>Nelson, Tyler J.</au><au>Kumar, Abhishek</au><au>Luterstein, Elaine</au><au>Yip, Anthony T.</au><au>Nalawade, Vinit</au><au>Parsons, J. Kellogg</au><au>Kader, A. Karim</au><au>Stewart, Tyler F.</au><au>Rose, Brent S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>127</volume><issue>23</issue><spage>4403</spage><epage>4412</epage><pages>4403-4412</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background
The safety of active surveillance (AS) for African American men compared with non‐Hispanic White (White) men with intermediate‐risk prostate cancer is unclear.
Methods
The authors identified patients with modified National Comprehensive Cancer Network favorable (“low‐intermediate”) and unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health Administration database. They analyzed definitive treatment, disease progression, metastases, prostate cancer–specific mortality (PCSM), and all‐cause mortality by using cumulative incidences and multivariable competing‐risks (disease progression, metastasis, and PCSM) or Cox (all‐cause mortality) regression.
Results
The cohort included 1007 men (African Americans, 330 [32.8%]; Whites, 677 [67.2%]) followed for a median of 7.7 years; 773 (76.8%) had low‐intermediate‐risk disease, and 234 (23.2%) had high‐intermediate‐risk disease. The 10‐year cumulative incidences of definitive treatment were not significantly different (African Americans, 83.5%; 95% confidence interval [CI], 78.5%‐88.7%; Whites, 80.6%; 95% CI, 76.6%‐84.4%; P = .17). Among those with low‐intermediate‐risk disease, there were no significant differences in the 10‐year cumulative incidences of disease progression (African Americans, 46.8%; 95% CI, 40.0%‐53.3%; Whites, 46.9%; 95% CI, 42.1%‐51.5%; P = .91), metastasis (African Americans, 7.1%; 95% CI, 3.7%‐11.8%; Whites, 10.8%; 95% CI, 7.6%‐14.6%; P = .17), or PCSM (African Americans, 3.8%; 95% CI, 1.6%‐7.5%; Whites, 3.8%; 95% CI, 2.0%‐6.3%; P = .69). In a multivariable regression including the entire cohort, African American race was not associated with increased risks of definitive treatment, disease progression, metastasis, PCSM, or all‐cause mortality (all P > .30).
Conclusions
Outcomes in the Veterans Affairs Health System were similar for African American and White men treated for low‐intermediate‐risk prostate cancer with AS.
The safety of active surveillance for African American men with intermediate‐risk prostate cancer is unclear. This study has measured similar clinical outcomes for African American men and non‐Hispanic White men treated for either modified National Comprehensive Cancer Network (NCCN) favorable (“low‐intermediate”) or unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer with active surveillance, and it suggests that active surveillance may be an appropriate option for both African American men and non‐Hispanic White men with modified NCCN favorable (“low‐intermediate”) intermediate‐risk prostate cancer.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34347291</pmid><doi>10.1002/cncr.33824</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3197-9552</orcidid><orcidid>https://orcid.org/0000-0002-7783-0016</orcidid><orcidid>https://orcid.org/0000-0001-7625-3678</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2021-12, Vol.127 (23), p.4403-4412 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_journals_2595120603 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | active surveillance African American African Americans clinical outcomes Confidence intervals Health risks Humans intermediate‐risk prostate cancer Male Metastases Metastasis Minority & ethnic groups Mortality Oncology Prostate cancer Prostate-Specific Antigen Prostatic Neoplasms - pathology Risk Statistical analysis Surveillance Veterans Health Administration Watchful Waiting Whites |
| title | Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A55%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Active%20surveillance%20for%20intermediate%E2%80%90risk%20prostate%20cancer%20in%20African%20American%20and%20non%E2%80%90Hispanic%20White%20men&rft.jtitle=Cancer&rft.au=Courtney,%20P.%20Travis&rft.date=2021-12-01&rft.volume=127&rft.issue=23&rft.spage=4403&rft.epage=4412&rft.pages=4403-4412&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.33824&rft_dat=%3Cproquest_cross%3E2595120603%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2595120603&rft_id=info:pmid/34347291&rfr_iscdi=true |